Servier Wins Reuters' 2022 Patient Champion Award
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, was the recipient of the Patient Champion...
Source: prnewswire.com
Page 2 - Interval Prolongation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Interval Prolongation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Interval Prolongation Today - Breaking & Trending Today
Servier to Showcase Growing Oncology Portfolio at the ASCO and EHA 2022 Annual Meetings
Wide range of research across tumor types underscores Servier's commitment to discovering novel approaches to addressing difficult-to-treat cancers Phase 3...
Source: prnewswire.com
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
Source: prnewswire.com
Servier Pharmaceuticals: Servier Announces FDA Approval of TIBSOVO (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
TIBSOVO is the first therapy targeting cancer metabolism approved in combination with azacitidine for patients with newly diagnosed IDH1-mutated acute myeloid leukemia FDA approval based
Source: finanznachrichten.de
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Newly Diagnosed IDH1-mutated Acute Myeloid Leukemia
/PRNewswire/ -- Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that the U.S. Food and...
Source: prnewswire.com